TY - JOUR AU - McCarthy, E. F. PY - 2006 DA - 2006// TI - The toxins of William B. Coley and the treatment of bone and soft tissue sarcomas JO - Iowa Ortho J VL - 26 ID - McCarthy2006 ER - TY - JOUR AU - Theoret, M. R. AU - Pai-Scherf, L. H. AU - Chuk, M. K. AU - Prowell, T. M. AU - Balasubramaniam, S. AU - Kim, T. PY - 2015 DA - 2015// TI - Expansion cohorts in first-in-human solid tumor oncology trials JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-14-3244 DO - 10.1158/1078-0432.CCR-14-3244 ID - Theoret2015 ER - TY - JOUR AU - Bates, S. E. AU - Berry, D. A. AU - Balasubramaniam, S. AU - Bailey, S. AU - LoRusso, P. M. AU - Rubin, E. H. PY - 2015 DA - 2015// TI - Advancing clinical trials to streamline drug development JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0039 DO - 10.1158/1078-0432.CCR-15-0039 ID - Bates2015 ER - TY - JOUR AU - Manji, A. AU - Brana, E. AU - Amir, E. AU - Tomlinson, G. AU - Tannock, I. F. AU - Beddard, P. I. PY - 2013 DA - 2013// TI - Evolution of clinical trial design in early drug development: systemic review of expansion cohort use in single-agent phase 1 cancer trials JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.47.4957 DO - 10.1200/JCO.2012.47.4957 ID - Manji2013 ER - TY - JOUR AU - Hamid, O. AU - Robert, C. AU - Daud, A. AU - Hodi, F. S. AU - Hwu, W. J. AU - Kefford, R. PY - 2013 DA - 2013// TI - Safety and tumor repsonses with lambrolizumab (anti-PD-1) in melanoma JO - N Engl J Med VL - 369 UR - https://doi.org/10.1056/NEJMoa1305133 DO - 10.1056/NEJMoa1305133 ID - Hamid2013 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Wolchok, J. D. AU - Hodi, F. S. AU - Hamid, O. AU - Kefford, R. PY - 2014 DA - 2014// TI - Anti-programmed death-receptor-1 treatment with pembrolizumab in ipillimumab-refractory advanced melanoma: a randomized dose comparison cohort of a phase 1 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60958-2 DO - 10.1016/S0140-6736(14)60958-2 ID - Robert2014 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Andtbacka, R. H. AU - Kaufman, H. L. AU - Collichio, F. AU - Amatruda, T. AU - Senzer, N. AU - Chesney, J. PY - 2015 DA - 2015// TI - Talimogene laherparepvec induces durable responses in patients with advanced melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3377 DO - 10.1200/JCO.2014.58.3377 ID - Andtbacka2015 ER - TY - JOUR AU - Kaufman, H. L. AU - Kohlhapp, F. J. AU - Zloza, A. PY - 2015 DA - 2015// TI - Oncolytic viruses: A new class of immunotherapy drugs JO - Nat Rev Drug Discov VL - 14 UR - https://doi.org/10.1038/nrd4663 DO - 10.1038/nrd4663 ID - Kaufman2015 ER - TY - JOUR AU - Senzer, N. N. AU - Kaufman, H. L. AU - Amatruda, T. AU - Nemunaitis, M. AU - Reid, T. AU - Daniels, G. PY - 2009 DA - 2009// TI - Phase II study of a GM-CSF encoding, second generation oncolytic herpesvirus in patients with unresectable metastatic melanoma JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.24.3675 DO - 10.1200/JCO.2009.24.3675 ID - Senzer2009 ER - TY - JOUR AU - Farewell, V. T. AU - D’Angio, G. J. PY - 1981 DA - 1981// TI - A simulated study of historical controls using real data JO - Biometrics VL - 37 UR - https://doi.org/10.2307/2530534 DO - 10.2307/2530534 ID - Farewell1981 ER - TY - JOUR AU - Suntharalingam, G. AU - Perry, M. R. AU - Ward, S. AU - Brett, S. J. AU - Castello-Cortes, A. AU - Brunner, M. D. AU - Panoskaltsis, N. PY - 2006 DA - 2006// TI - Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa063842 DO - 10.1056/NEJMoa063842 ID - Suntharalingam2006 ER - TY - JOUR AU - Hunig, T. PY - 2012 DA - 2012// TI - The storm has cleared: lessons from the CD28 superagonist TGN1412 trial JO - Nature Rev Immunol VL - 12 UR - https://doi.org/10.1038/nri3192-c2 DO - 10.1038/nri3192-c2 ID - Hunig2012 ER - TY - JOUR AU - Grupp, S. A. AU - Kalos, M. AU - Barrett, D. AU - Aplenc, R. AU - Porter, D. L. AU - Rheingold, S. R. PY - 2013 DA - 2013// TI - Chimeric antigen receptor-modified T cells for acute lymphoid leukemia JO - N Engl J Med VL - 368 UR - https://doi.org/10.1056/NEJMoa1215134 DO - 10.1056/NEJMoa1215134 ID - Grupp2013 ER - TY - JOUR AU - Porter, D. L. AU - Hwang, W. T. AU - Frey, N. V. AU - Lacey, S. F. AU - Shaw, P. A. AU - Loren, A. W. PY - 2015 DA - 2015// TI - Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac5415 DO - 10.1126/scitranslmed.aac5415 ID - Porter2015 ER - TY - JOUR AU - Defrancesco, L. PY - 2014 DA - 2014// TI - CAR-T cell therapy seeks strategies to harness cytokine storm JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt0714-604 DO - 10.1038/nbt0714-604 ID - Defrancesco2014 ER - TY - JOUR AU - Lee, D. W. AU - Gardner, R. AU - Porter, D. L. AU - Louis, C. U. AU - Ahmed, N. AU - Jensen, M. PY - 2014 DA - 2014// TI - Current concepts in the diagnosis and management of cytokine release syndrome JO - Blood VL - 124 UR - https://doi.org/10.1182/blood-2014-05-552729 DO - 10.1182/blood-2014-05-552729 ID - Lee2014 ER - TY - STD TI - Davila ML, Riviere I, Wang X Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25. ID - ref18 ER - TY - JOUR AU - Linette, G. P. AU - Stadtmauer, E. A. AU - Maus, M. V. AU - Rapoport, A. P. AU - Levine, B. L. AU - Emery, L. PY - 2013 DA - 2013// TI - Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-03-490565 DO - 10.1182/blood-2013-03-490565 ID - Linette2013 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O’Day, S. AU - Weber, J. S. AU - Hamid, O. AU - Lebbe, C. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - JOUR AU - Tirkes, T. AU - Hollar, M. A. AU - Tann, M. AU - Kohli, M. D. AU - Akisik, F. AU - Sandrasegaran, K. PY - 2013 DA - 2013// TI - Response criteria in oncologic imaging: review of traditional and new critera JO - Radiographics VL - 33 UR - https://doi.org/10.1148/rg.335125214 DO - 10.1148/rg.335125214 ID - Tirkes2013 ER - TY - JOUR AU - Hodi, F. S. AU - Hwu, W. J. AU - Kefford, R. AU - Weber, J. S. AU - Daud, A. AU - Hamid, O. PY - 2016 DA - 2016// TI - Evaluation of immune-related response criteria and RECISTv1.1 in patients with advanced melanoma treated with pembrolizumab JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.0391 DO - 10.1200/JCO.2015.64.0391 ID - Hodi2016 ER - TY - JOUR AU - Hughes, T. AU - Klairmont, M. AU - Broucek, J. AU - Iodice, G. AU - Basu, S. AU - Kaufman, H. L. PY - 2015 DA - 2015// TI - The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma JO - Cancer Immunol Immunother VL - 64 UR - https://doi.org/10.1007/s00262-014-1652-6 DO - 10.1007/s00262-014-1652-6 ID - Hughes2015 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined nivolumab and ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus doctaxel in advanced squamous-cell non-small cell lung cancr JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Yuan, J. AU - Hegde, P. S. AU - Clynes, R. AU - Foukas, P. G. AU - Harari, A. AU - Kleen, T. O. PY - 2016 DA - 2016// TI - Novel technologies and emerging biomarkers for personalized cancer immunotherapy JO - J Immunother Cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0107-3 DO - 10.1186/s40425-016-0107-3 ID - Yuan2016 ER -